28/06/2010
Commercial Developments
At todays AGM the Chairman of ReGen Therapeutics Plc (‘ReGen’ or the ‘Company’) commented that since the Chairman’s Statement of 3 June 2010 there are additional points which we would like to draw to the attention of shareholders.
There have been encouraging developments in revenue generation. Estimated revenues for the first half of 2010 are £132,000 compared with total revenues in 2009 of £56,055. This revenue has come from several of the markets where Colostrinin™ is now on sale and we look to continue this upward trend.
Our Turkish licensee Eczacibasi Ilac Pazarlama A.S (‘Eczacibasi’)1 has now confirmed that it has launched ReGen’s nutritional supplement Colostrinin™ under the local tradename ‘Dyna™’ in the Republic of Turkey.
Since obtaining final product approval on 4 May 2010 Eczacibasi have built a new marketing and sales team to launch the product and have introduced the product to key opinion leaders in the market prior to formal launch.
By way of reminder Eczacibasi are supplied with bulk blistered tablets for which ReGen receive a fee for the active ingredient component. These are then packaged locally. Revenues to ReGen from Eczacibasi pursuant to the minimum annual purchase commitments in the distribution agreement are estimated to be $52,000 in the first year and $104,000 in the second year.
We would also comment that the other aspects of the business are developing as described in the Chairman’s Statement of 3 June. In particular a combination of fundraising and sales with continuing attention to costs has improved the Company’s financial position since the year end.
Science Update
Zolpidem
South African SPECT Scanning Study – Full Publication
The full paper reporting the results of the SPECT scanning study in South Africa (first announced in a ReGen press release of 9 November 2009) was published in the journal Arzneimittel Forschung/ Drug Research. An abstract is available at http://www.ncbi.nlm.nih.gov/sites/pubmed by searching under the authors names:
Nyakale NE, Clauss RP, Nel HW, Sathekge MM.
Zolpidem Website
A website drawing together all of the currently available scientific information on the use of zolpidem in brain trauma has been put together and will be maintained by Dr Ralf Clauss (http://sites.google.com/site/zolpidemtherapy/).
There is now a link to this from the ReGen website.
Mode of Action Hypothesis Paper
A paper proposing how zolpidem works to overcome the natural brain response to trauma has been published by Dr Clauss.
http://www.ncbi.nim.nih.gov/pubmed/20347531
Colostrinin™
Austen/Stewart publications – J Nutr and Aging
A publication, by Prof Brian Austen (a former scientific collaborator of ReGen) and a subsequent letter from Dr M. Stewart (a former collaborator and consultant to ReGen) further elaborate on the mechanism of how Colostrinin™ can protect human neurones in-vitro from cell death (apoptosis) induced by aggregated beta amyloid and suggest that this mechanism might be the basis of Colostrinin’s™ protective effect in Alzheimer’s disease.
Abstracts of both articles are available at:
http://www.ncbi.nlm.nih.gov/sites/pubmed by searching under the authors names. Douraghi-Zadeh D, Matharu B, Razvi A, Austen B. and Stewart M.G respectively.
For further information, please contact:
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396
David Scott/Nick Bealer
Alexander David Securities Limited
Tel: 020 7448 9820
1 Eczacibasi
http://www.eczacibasi.com is a leading Turkish industrials group with 40 companies, approximately 9,300 employees and revenues of $3.2bn in 2007. Eczacibasi’s Ilac Pazarlama A.S. division is based in Levent-Istanbul, Turkey.